Nothing Special   »   [go: up one dir, main page]

CL2021002104A1 - Compuestos, composiciones y métodos. - Google Patents

Compuestos, composiciones y métodos.

Info

Publication number
CL2021002104A1
CL2021002104A1 CL2021002104A CL2021002104A CL2021002104A1 CL 2021002104 A1 CL2021002104 A1 CL 2021002104A1 CL 2021002104 A CL2021002104 A CL 2021002104A CL 2021002104 A CL2021002104 A CL 2021002104A CL 2021002104 A1 CL2021002104 A1 CL 2021002104A1
Authority
CL
Chile
Prior art keywords
methods
compositions
compounds
stereoisomer
stereoisomers
Prior art date
Application number
CL2021002104A
Other languages
English (en)
Inventor
Maksim Osipov
Vicente Fidalgo Javier De
Robert A Ii Craig
Anthony A Estrada
Jianwen A Feng
Brian M Fox
Arun Thottumkara
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CL2021002104A1 publication Critical patent/CL2021002104A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente descripción hace referencia en términos generales a moduladores del factor de iniciación eucariota 2B o una sal farmacéuticamente aceptable, un estereoisómero, una mezcla de estereoisómeros o un profármaco de estos y a métodos para realizarlos y utilizarlos.
CL2021002104A 2019-02-13 2021-08-10 Compuestos, composiciones y métodos. CL2021002104A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805263P 2019-02-13 2019-02-13
US201962877232P 2019-07-22 2019-07-22

Publications (1)

Publication Number Publication Date
CL2021002104A1 true CL2021002104A1 (es) 2022-04-08

Family

ID=72043948

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002104A CL2021002104A1 (es) 2019-02-13 2021-08-10 Compuestos, composiciones y métodos.

Country Status (19)

Country Link
US (2) US11306077B2 (es)
EP (1) EP3923935A4 (es)
JP (1) JP2022520236A (es)
KR (1) KR20210126036A (es)
CN (1) CN113518618A (es)
AU (1) AU2020223228A1 (es)
BR (1) BR112021015639A2 (es)
CA (1) CA3129609A1 (es)
CL (1) CL2021002104A1 (es)
CO (1) CO2021010490A2 (es)
CR (1) CR20210426A (es)
IL (1) IL285302A (es)
MA (1) MA54953A (es)
MX (1) MX2021009669A (es)
PE (1) PE20212023A1 (es)
SA (1) SA521430021B1 (es)
SG (1) SG11202108552QA (es)
TW (1) TW202045164A (es)
WO (1) WO2020168011A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001352A (es) 2017-08-09 2020-03-20 Denali Therapeutics Inc Compuestos, composiciones y metodos.
CA3085132A1 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
KR20210021519A (ko) 2018-06-05 2021-02-26 프락시스 바이오테크 엘엘씨 통합 스트레스 반응 경로의 저해제
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
KR20210126036A (ko) 2019-02-13 2021-10-19 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
US11318133B2 (en) 2019-06-12 2022-05-03 Praxis Biotech LLC Modulators of integrated stress response pathway
JP2023517944A (ja) 2020-03-11 2023-04-27 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合的ストレス応答経路の調節因子
KR20230110509A (ko) 2020-10-22 2023-07-24 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
WO2022084446A1 (en) 2020-10-22 2022-04-28 Evotec International Gmbh Modulators of the integrated stress response pathway
AU2021363616A1 (en) 2020-10-22 2023-06-22 Evotec International Gmbh Modulators of the integrated stress response pathway
EP4263488A1 (en) * 2020-12-18 2023-10-25 Denali Therapeutics Inc. Solid forms of a compound
WO2024032501A1 (zh) * 2022-08-08 2024-02-15 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
CA2315050C (en) 1998-10-16 2009-02-03 Suntory Limited Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
AU2001249417A1 (en) * 2000-04-26 2001-11-07 Gliatech, Inc. Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
EP1390034A4 (en) * 2001-04-03 2005-07-13 Merck & Co Inc NMDA / NR2B NONARYL-HETEROCYCLO AMIDYL N-SUBSTITUTE ANTAGONISTS
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
DE602005015231D1 (de) 2004-09-02 2009-08-13 Vertex Pharma Als ionenkanalmodulatoren geeignete chinazoline
EP1891078A1 (en) 2005-05-24 2008-02-27 AstraZeneca AB Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
UA96283C2 (uk) * 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
CA2666482A1 (en) 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
AU2008263397B2 (en) 2007-06-15 2013-12-05 Idorsia Pharmaceuticals Ltd 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives
TWI426076B (zh) 2008-12-12 2014-02-11 Actelion Pharmaceuticals Ltd ５－胺基－２－（１－羥基－乙基）－四氫哌喃衍生物
AU2010253820A1 (en) 2009-05-28 2011-12-22 President And Fellows Of Harvard College N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation
CN102458408B (zh) 2009-06-17 2015-06-03 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
TWI538905B (zh) 2010-12-22 2016-06-21 Ｈ 朗德貝克公司 雙環［３．２．１］辛基醯胺衍生物及其用途
CN103403002B (zh) 2011-02-24 2016-06-22 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
HUE038714T2 (hu) 2011-03-10 2018-11-28 Daiichi Sankyo Co Ltd Dispiropirrolidin származék
LT2699553T (lt) 2011-04-22 2024-02-12 Signal Pharmaceuticals, Llc Pakeistas diaminokarboksamidas ir diaminokarbonitrilo pirimidinai, jų kompozicijos ir gydymo būdai
JP2015512873A (ja) * 2012-02-14 2015-04-30 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 殺線虫性のシス（ヘテロ）アリールシクロプロピルカルボキサミド誘導体
CN104837820A (zh) 2012-10-02 2015-08-12 大日本住友制药株式会社 咪唑衍生物
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
WO2015038778A1 (en) 2013-09-11 2015-03-19 The Brigham And Women's Hospital, Inc. SUBSTITUTED UREA EIF2α KINASE ACTIVATORS
CA2944669A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6833677B2 (ja) 2014-09-17 2021-02-24 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 二環式化合物
KR20170086057A (ko) 2014-11-20 2017-07-25 메르크 파텐트 게엠베하 Irak 억제제로서 헤테로아릴 화합물 및 이들의 용도
ES2764660T3 (es) 2014-12-16 2020-06-04 Axovant Sciences Gmbh Compuestos de amida de quinuclidina sustituida geminal como agonistas de receptores alfa-7 nicotínicos de acetilcolina
PE20180355A1 (es) 2015-02-25 2018-02-21 Univ Rice William M Desacetoxitubulisina h y analogos de esta
GB201506894D0 (en) * 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CR20170509A (es) 2015-05-05 2018-04-16 Bayer Pharma AG Derivados de ciclohexano sustituido con amido
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TWI763668B (zh) * 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
RU2018145734A (ru) 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
AU2017279027A1 (en) * 2016-06-08 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
CA3029883A1 (en) 2016-07-06 2018-01-11 Acquist Llc Compounds and their use for reducing uric acid levels
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
CA3045947A1 (en) 2016-12-08 2018-06-14 Michael J. Soth Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
US11180490B2 (en) * 2017-06-09 2021-11-23 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CA3068395A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1-(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
US20210145771A1 (en) * 2017-07-03 2021-05-20 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
MX2020001352A (es) 2017-08-09 2020-03-20 Denali Therapeutics Inc Compuestos, composiciones y metodos.
JP7382308B2 (ja) 2017-09-01 2023-11-16 デナリ セラピューティクス インコーポレイテッド 化合物、組成物、及び、方法
WO2019054430A1 (ja) 2017-09-14 2019-03-21 第一三共株式会社 芳香族複素環を有するアミド化合物
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP7307057B2 (ja) 2017-11-02 2023-07-11 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
CA3080808A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
US20210205277A1 (en) 2017-11-02 2021-07-08 Calico Life Sciences Llc Modulators of the integrated stress pathway
CN112218851A (zh) 2017-11-02 2021-01-12 卡里科生命科学有限责任公司 整合应激通路的调节剂
AU2018358160B2 (en) 2017-11-02 2023-03-16 Abbvie Inc. Modulators of the integrated stress pathway
SG11202004074TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
CA3085132A1 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
US20210253528A1 (en) 2018-07-09 2021-08-19 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
TWI832295B (zh) 2018-10-11 2024-02-11 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
KR20210126036A (ko) 2019-02-13 2021-10-19 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
WO2020181247A1 (en) 2019-03-06 2020-09-10 Denali Therapeutics Inc. Compounds, compositions and methods
CN113993850B (zh) * 2019-04-23 2024-03-29 埃沃特克国际有限责任公司 整合应激反应途径的调节剂
AR118836A1 (es) 2019-04-30 2021-11-03 Calico Life Sciences Llc Moduladores de la vía de tensión integrada
CN114206848A (zh) 2019-04-30 2022-03-18 卡里科生命科学有限责任公司 作为整合应激通路的调节剂的被取代的环烷基化合物
EP4096665A1 (en) * 2020-01-28 2022-12-07 Evotec International GmbH Modulators of the integrated stress response pathway
EP4263488A1 (en) 2020-12-18 2023-10-25 Denali Therapeutics Inc. Solid forms of a compound

Also Published As

Publication number Publication date
SG11202108552QA (en) 2021-09-29
IL285302A (en) 2021-09-30
JP2022520236A (ja) 2022-03-29
KR20210126036A (ko) 2021-10-19
MA54953A (fr) 2021-12-22
EP3923935A4 (en) 2022-10-26
MX2021009669A (es) 2021-10-13
CA3129609A1 (en) 2020-08-20
AU2020223228A1 (en) 2021-08-26
PE20212023A1 (es) 2021-10-18
SA521430021B1 (ar) 2024-08-11
US11306077B2 (en) 2022-04-19
BR112021015639A2 (pt) 2021-10-05
US11958840B2 (en) 2024-04-16
EP3923935A1 (en) 2021-12-22
CO2021010490A2 (es) 2021-08-30
WO2020168011A1 (en) 2020-08-20
US20210292311A1 (en) 2021-09-23
US20230114472A1 (en) 2023-04-13
TW202045164A (zh) 2020-12-16
CR20210426A (es) 2021-09-30
CN113518618A (zh) 2021-10-19

Similar Documents

Publication Publication Date Title
CL2021002104A1 (es) Compuestos, composiciones y métodos.
CO2020001220A2 (es) Compuestos, composiciones y métodos
EP4248965A3 (en) Compounds, compositions and methods
UY38990A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
PE20241068A1 (es) Moduladores de profarmacos de la via de estres integrada
CL2019002204A1 (es) Compuestos inhibidores del vih.
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
AR109561A1 (es) Compuestos modulares de receptores tipo toll
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
CL2017001017A1 (es) Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
CL2021001461A1 (es) Moduladores de trex1
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
EA202193015A1 (ru) Ингибиторы cdk
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
NI202100012A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
CO2022008719A2 (es) Compuestos para modular la actividad de fxr y usos de los mismos
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
EA202192121A1 (ru) Соединения, составы и способы
EA202090138A1 (ru) Соединения, составы и способы